<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36841740</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.</ArticleTitle><Pagination><StartPage>832</StartPage><EndPage>840</EndPage><MedlinePgn>832-840</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2023.02.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(23)00176-8</ELocationID><Abstract><AbstractText>Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bucciol</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, Leuven, Belgium; Childhood Immunology, Department of Pediatrics, Leuven University Hospitals, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID Human Genetic Effort</CollectiveName></Author><Author ValidYN="Y"><LastName>Meyts</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, Leuven, Belgium; Childhood Immunology, Department of Pediatrics, Leuven University Hospitals, Leuven, Belgium. Electronic address: isabelle.meyts@uzleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI088364</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI163029</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024143</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">multisystem inflammatory syndrome in children</Keyword><Keyword MajorTopicYN="N">type I interferon</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Abel</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Muhsen</LastName><ForeName>Salah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiuti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Mulla</LastName><ForeName>Fahd</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreakos</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonio</LastName><ForeName>Novelli</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arias</LastName><ForeName>Andr&#xe9;s A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trouillet-Assant</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belot</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biggs</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bousfiha</LastName><ForeName>Ahmed A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bolze</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borghesi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brodin</LastName><ForeName>Petter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christodoulou</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cobat</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Condino-Neto</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalgard</LastName><ForeName>Clifton L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinosa-Padilla</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fellay</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Froidure</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorochov</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haerynck</LastName><ForeName>Filomeen</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halwani</LastName><ForeName>Rabih</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Elena W Y</ForeName><Initials>EWY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Itan</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kisand</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lau</LastName><ForeName>Yu-Lung</ForeName><Initials>YL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mansouri</LastName><ForeName>Davood</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyts</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mogensen</LastName><ForeName>Trine H</ForeName><Initials>TH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>Lisa F P</ForeName><Initials>LFP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Notarangelo</LastName><ForeName>Luigi D</ForeName><Initials>LD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novelli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okada</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozcelik</LastName><ForeName>Tayfun</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez de Diego</LastName><ForeName>Rebeca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prando</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pujol</LastName><ForeName>Aurora</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quintana-Murci</LastName><ForeName>Lluis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renia</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resnick</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roussel</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez-Gallego</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sancho-Shimizu</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shahrooei</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soler-Palac&#xed;n</LastName><ForeName>Pere</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spaan</LastName><ForeName>Andr&#xe1;s N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tancevski</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tangye</LastName><ForeName>Stuart G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tayoun</LastName><ForeName>Ahmad Abou</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temel</LastName><ForeName>&#x15e;ehime G&#xfc;ls&#xfc;n</ForeName><Initials>&#x15e;G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tur</LastName><ForeName>Jordi Perez</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turvey</LastName><ForeName>Stuart E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uddin</LastName><ForeName>Furkan</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uddin</LastName><ForeName>Mohammed J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidigal</LastName><ForeName>Mateus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinh</LastName><ForeName>Donald C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zatz</LastName><ForeName>Mayana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlin</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pesole</LastName><ForeName>Graziano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorball</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Beek</LastName><ForeName>Diederik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colobran</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wauters</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shen-Ying</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Helen C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casanova</LastName><ForeName>Jean-Laurent</ForeName><Initials>JL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>22</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36841740</ArticleId><ArticleId IdType="pmc">PMC9951110</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2023.02.003</ArticleId><ArticleId IdType="pii">S0091-6749(23)00176-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., et al. Early Transmission dynamics in wuhan, china, of novel coronavirus&#x2013;infected pneumonia. N Engl J Med. 2020;382:1199&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region. Italy. JAMA. 2020;323:1574&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G., Moens L., Bosch B., Bossuyt X., Casanova J.L., Puel A., et al. Lessons learned from the study of human inborn errors of innate immunity. J Allergy Clin Immunol. 2019;143:507&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358521</ArticleId><ArticleId IdType="pubmed">30075154</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M.S., Kanneganti T.D. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022;23:165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R., Okell L.C., Dorigatti I., Winskill P., Whittaker C., Imai N., et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Carius B.M., Chavez S., Liang S.Y., Brady W.J., Koyfman A., et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022;54:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779861</ArticleId><ArticleId IdType="pubmed">35121478</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Driscoll M., Ribeiro Dos Santos G., Wang L., Cummings D.A.T., Azman A.S., Paireau J., et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">33137809</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J.L., Su H.C., Abel L., Aiuti A., Almuhsen S., Arias A.A., et al. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181:1194&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218368</ArticleId><ArticleId IdType="pubmed">32405102</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi M.E.K., Karjalainen J., Liao R.G., Neale B.M., Daly M., Ganna A., et al. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E., Clohisey S., Klaric L., Bretherick A.D., Rawlik K., Pasko D., et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Severe Covid-19 GWAS Group. Aghemo A., Angelini C., Badalamenti S., Balzarini L., Bocciolone M., et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton J.F., Shastri A.J., Ye C., Weldon C.H., Filshtein-Sonmez T., Coker D., et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet. 2021;53:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">33888907</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyts I., Bucciol G., Quinti I., Neven B., Fischer A., Seoane E., et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147:520&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832563</ArticleId><ArticleId IdType="pubmed">32980424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Pen J.L., Moncada-Velez M., Chen J., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell T.M., Liu Z., Zhang Q., Moncada-Velez M., Covill L.E., Zhang P., et al. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. J Exp Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178406</ArticleId><ArticleId IdType="pubmed">35670811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciancanelli M.J., Huang S.X.L., Luthra P., Garner H., Itan Y., Volpi S., et al. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science. 2015;348:448&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431581</ArticleId><ArticleId IdType="pubmed">25814066</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolhassani H., Landegren N., Bastard P., Materna M., Modaresi M., Du L., et al. Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J Clin Immunol. 2022;42:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798309</ArticleId><ArticleId IdType="pubmed">35091979</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S., Rezaei N., Khazaei M., Shirkani A. A case of autosomal recessive interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J Clin Immunol. 2022;42:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553400</ArticleId><ArticleId IdType="pubmed">34713375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Matuozzo D., Le Pen J., Lee D., Moens L., Asano T., et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T., Boisson B., Onodi F., Matuozzo D., Moncada-Velez M., Renkilaraj M., et al. X-linked recessive TLR7 deficiency in &#x223c;1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanich X., Vargas-Parra G., van der Made C.I., Simons A., Schuurs-Hoeijmakers J., Antol&#xed; A., et al. Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343010</ArticleId><ArticleId IdType="pubmed">34367187</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Made C.I., Simons A., Schuurs-Hoeijmakers J., van den Heuvel G., Mantere T., Kersten S., et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324:663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382021</ArticleId><ArticleId IdType="pubmed">32706371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H.K., Huang S.X.L., Chen J., Kerner G., Gilliaux O., Bastard P., et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. J Exp Med. 2019;216:2038&#x2013;2056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719423</ArticleId><ArticleId IdType="pubmed">31217193</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A., Peters S., Knaus A., Sabir H., Hamsen F., Maj C., et al. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom Med. 2021;6:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249618</ArticleId><ArticleId IdType="pubmed">34210994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood H.Z., Madhavarapu S., Almuqamam M. Varying illness severity in patients with MyD88 deficiency infected with coronavirus SARS-CoV-2 [meeting abstract] Pediatrics. 2021;147:453&#x2013;454.</Citation></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Orlova E., Sozaeva L., L&#xe9;vy R., James A., Schmitt M.M., et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Gervais A., Le Voyer T., Rosain J., Philippot Q., Manry J., et al. Autoantibodies neutralizing type I IFNs are present in &#x223c;4% of uninfected individuals over 70 years old and account for &#x223c;20% of COVID-19 deaths. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J., Bastard P., Gervais A., Le Voyer T., Rosain J., Philippot Q., et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173764</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Vazquez S., Liu J., Laurie M.T., Wang C.Y., Gervais A., et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol. 2022;0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210448</ArticleId><ArticleId IdType="pubmed">35857576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., COVID Human Genetic Effort. Karbuz A., Gervais A., Tayoun A.A., et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Gervais A., Le Voyer T., Rosain J., Philippot Q., Manry J., et al. Autoantibodies neutralizing type I IFNs are present in &#x223c;4% of uninfected individuals over 70 years old and account for &#x223c;20% of COVID-19 deaths. Sci Immunol. 2021;6(62)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou J., Platt C.D., Habiballah S., Nguyen A.A., Elkins M., Weeks S., et al. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C) J Allergy Clin Immunol. 2021;142:732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252701</ArticleId><ArticleId IdType="pubmed">34224783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.Y., Platt C.D., Weeks S., Grace R.F., Maher G., Gauthier K., et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020;146:1194&#x2013;1200.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445138</ArticleId><ArticleId IdType="pubmed">32853638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D., Le Pen J., Yatim A., Dong B., Aquino Y., Ogishi M., et al. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. Science. 2022;0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10451000</ArticleId><ArticleId IdType="pubmed">36538032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinh D.C., Abel L., Bastard P., Cheng M.P., Condino-Neto A., Gregersen P.K., et al. Harnessing type I interferon immunity against SARS-CoV-2 with early administration of IFN-&#x3b2;. J Clin Immunol. 2021;41:1425&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186356</ArticleId><ArticleId IdType="pubmed">34101091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Bolze A., Jouanguy E., Zhang S.Y., Cobat A., et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y) 2020;1:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748410</ArticleId><ArticleId IdType="pubmed">33363283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G., Tangye S.G., Meyts I. Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned. Curr Opin Pediatr. 2021;33:648&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577305</ArticleId><ArticleId IdType="pubmed">34734915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez N., Bucciol G., Moens L., Le Pen J., Shahrooei M., Goudouris E., et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216:2057&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719432</ArticleId><ArticleId IdType="pubmed">31270247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothe F., Hatton C.F., Truong L., Klimova Z., Kanderova V., Fejtkova M., et al. A novel case of homozygous interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with hemophagocytic lymphohistiocytosis. Clin Infect Dis. 2020;74:136&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752251</ArticleId><ArticleId IdType="pubmed">33252644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Manry J., Chen J., Rosain J., Seeleuthner Y., AbuZaitun O., et al. Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency. J Clin Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773360</ArticleId><ArticleId IdType="pubmed">32960813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Hsiao K.C., Zhang Q., Choin J., Best E., Chen J., et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J Exp Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026234</ArticleId><ArticleId IdType="pubmed">35442418</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C.J.A., Mohamad S.M.B., Young D.F., Skelton A.J., Leahy T.R., Munday D.C., et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926955</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C.J.A., Skouboe M.K., Howarth S., Hollensen A.K., Chen R., B&#xf8;rresen M.L., et al. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. J Exp Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026249</ArticleId><ArticleId IdType="pubmed">35442417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G., Moens L., Corveleyn A., Dreesman A., Meyts I. A novel kindred with MyD88 deficiency. J Clin Immunol. 2022:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919685</ArticleId><ArticleId IdType="pubmed">35286514</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Garc&#xed;a A, P&#xe9;rez de Diego R, Flores C, Rinchai D, Sol&#xe9;-Viol&#xe1;n J, &#xc0;ngela Dey&#xe0;-Mart&#xed;nez, et al. Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. J Exp Med, 10.1084/jem.20220170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220170</ArticleId><ArticleId IdType="pmc">PMC9998661</ArticleId><ArticleId IdType="pubmed">36880831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T., Morrison T.E., Funkhouser W., Uematsu S., Akira S., Baric R.S., et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLOS Pathog. 2008;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587915</ArticleId><ArticleId IdType="pubmed">19079579</ArticleId></ArticleIdList></Reference><Reference><Citation>Onodi F., Bonnet-Madin L., Meertens L., Karpf L., Poirot J., Zhang S.Y., et al. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4 SARS-CoV-2 and plasmacytoid predendritic cells. J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849819</ArticleId><ArticleId IdType="pubmed">33533916</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuozzo D, Talouarn E, Marchal A, Manry J, Seeleuthner Y, Zhang Y, et&#xa0;al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 2022;2022.10.22.22281221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10074346</ArticleId><ArticleId IdType="pubmed">37020259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kousathanas A., Pairo-Castineira E., Rawlik K., Stuckey A., Odhams C.A., Walker S., et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022;607:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259496</ArticleId><ArticleId IdType="pubmed">35255492</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J.L., Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022;185:3086&#x2013;3103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9386946</ArticleId><ArticleId IdType="pubmed">35985287</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;ffinger R., Helbert M.R., Barcenas-Morales G., Yang K., Dupuis S., Ceron-Gutierrez L., et al. Autoantibodies to interferon-&#x3b3; in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38:e10&#x2013;e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">14679469</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel A., Picard C., Lorrot M., Pons C., Chrabieh M., Lorenzo L., et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180:647&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisand K., B&#xf8;e Wolff A.S., Podkraj&#x161;ek K.T., Tserel L., Link M., Kisand K.V., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822605</ArticleId><ArticleId IdType="pubmed">20123959</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku C.L., Chi C.Y., von Bernuth H., Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet. 2020;139:783&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272486</ArticleId><ArticleId IdType="pubmed">32419033</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel A., D&#xf6;ffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207:291&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822614</ArticleId><ArticleId IdType="pubmed">20123958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallbracht A., Treuner J., Flehmig B., Joester K.E., Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 1981;289:496&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">6162104</ArticleId></ArticleIdList></Reference><Reference><Citation>Panem S., Check I.J., Henriksen D., Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982;129:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">6177744</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J.E., Rosen L.B., Csomos K., Rosenberg J.M., Mathew D., Keszei M., et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015;125:4135&#x2013;4148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639965</ArticleId><ArticleId IdType="pubmed">26457731</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M. Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1. PLOS Med. 2006 giu;3:e292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1475656</ArticleId><ArticleId IdType="pubmed">16756392</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson D., Bacchetta R., Gunnarsson H.I., Chan A., Barzaghi F., Ehl S., et al. The autoimmune targets in IPEX are dominated by gut epithelial proteins. J Allergy Clin Immunol. 2019;144:327&#x2013;330.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31027649</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiono H., Wong Y.L., Matthews I., Liu J., Zhang W., Sims G., et al. Spontaneous production of anti-IFN-&#x3b1; and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003;15:903&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12882828</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg J.M., Maccari M.E., Barzaghi F., Allenspach E.J., Pignata C., Weber G., et al. Neutralizing anti-cytokine autoantibodies against interferon-&#x3b1; in immunodysregulation polyendocrinopathy enteropathy X-linked. Front Immunol. 2018;9:544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885158</ArticleId><ArticleId IdType="pubmed">29651287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzetto B., Mogensen K.E., Tovey M.G., Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984;150:707&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">6238105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen K.E., Daubas P., Gresser I., Sereni D., Varet B. patient with circulating antibodies to &#x3b1;-interferon. Lancet. 1981;318:1227&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">6171694</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer S., Woodward M., Hertel C., Vlaicu P., Haque Y., K&#xe4;rner J., et al. AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell. 2016;166:582&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967814</ArticleId><ArticleId IdType="pubmed">27426947</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccuti G., Ghizzoni L., Cambria V., Codullo V., Sacchi P., Lovati E., et al. A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor. J Endocrinol Invest. 2020;43:1175&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282538</ArticleId><ArticleId IdType="pubmed">32519200</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst M.G.P., Vazquez S.E., Hartoularos G.C., Bastard P., Grant T., Bueno R., et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Simula E.R., Manca M.A., Noli M., Jasemi S., Ruberto S., Uzzau S., et al. Increased presence of antibodies against type i interferons and human endogenous retrovirus w in intensive care unit COVID-19 patients. Microbiol Spectr. 2022;10 e01280-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9430400</ArticleId><ArticleId IdType="pubmed">35852349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A., Breillat P., Dorgham K., Bastard P., Charre C., Lhote R., et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-&#x3b1;. Ann Rheum Dis. 2022;81:1695&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">35973806</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca F., Scordio M., Santinelli L., Gabriele L., Gandini O., Criniti A., et al. Anti-IFN-&#x3b1;/-&#x3c9; neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur J Immunol. 2022;52:1120&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9087404</ArticleId><ArticleId IdType="pubmed">35419822</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbil B., Meyer T., Stubbemann P., Thibeault C., Staudacher O., Niemeyer D., et al. Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies. J Clin Immunol. 2022;42:1111&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069123</ArticleId><ArticleId IdType="pubmed">35511314</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto S., Nukui Y., Tsumura M., Nakagama Y., Kashimada K., Mizoguchi Y., et al. Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19. J Clin Immunol. 2022:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243824</ArticleId><ArticleId IdType="pubmed">35764767</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvineau-Grenier A., Bastard P., Servajean A., Gervais A., Rosain J., Jouanguy E., et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J Clin Immunol. 2022;42:459&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791677</ArticleId><ArticleId IdType="pubmed">35083626</ArticleId></ArticleIdList></Reference><Reference><Citation>Busnadiego I., Abela I.A., Frey P.M., Hofmaenner D.A., Scheier T.C., Schuepbach R.A., et al. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLOS Biol. 2022;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286229</ArticleId><ArticleId IdType="pubmed">35788562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari R., Rosen L.B., Lisco A., Gilden D., Holland S.M., Zerbe C.S., et al. Primary and acquired immunodeficiencies associated with severe varicella-zoster virus infections. Clin Infect Dis. 2021;73:e2705&#x2013;e2712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8563170</ArticleId><ArticleId IdType="pubmed">32856043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetem&#xe4;ki I., Laakso S., V&#xe4;limaa H., Kleino I., Kek&#xe4;l&#xe4;inen E., M&#xe4;kitie O., et al. Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin Immunol. 2021;231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425955</ArticleId><ArticleId IdType="pubmed">34508889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Pizzorno A., Miorin L., Bastard P., Gervais A., Le Voyer T., et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485705</ArticleId><ArticleId IdType="pubmed">36112363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Michailidis E., Hoffmann H.H., Chbihi M., Le Voyer T., Rosain J., et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871457</ArticleId><ArticleId IdType="pubmed">33544838</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L., Mazza A., Gervasoni A., Martelli L., Ruggeri M., Ciuffreda M., et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Toubiana J., Cohen J.F., Brice J., Poirault C., Bajolle F., Curtis W., et al. Distinctive features of Kawasaki disease following SARS-CoV-2 infection: a controlled study in Paris, France. J Clin Immunol. 2021;41:526&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7780601</ArticleId><ArticleId IdType="pubmed">33394320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho-Shimizu V., Brodin P., Cobat A., Biggs C.M., Toubiana J., Lucas C.L., et al. SARS-CoV-2-related MIS-C: a key to the viral and genetic causes of Kawasaki disease? J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080850</ArticleId><ArticleId IdType="pubmed">33904890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber C.N., Patel R.S., Trachtman R., Lepow L., Amanat F., Krammer F., et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Cell. 2020;183:982&#x2013;995.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L.R., Rose E.B., Horwitz S.M., Collins J.P., Newhams M.M., Son M.B.F., et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., M&#xf8;ller R., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Castro C.N., Tusseau M., Stolzenberg M.C., Mazerolles F., Aladjidi N., et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020;11:5341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578789</ArticleId><ArticleId IdType="pubmed">33087723</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudde A.C.A., Booth C., Marsh R.A. Evolution of our understanding of XIAP Deficiency. Front Pediatr. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247594</ArticleId><ArticleId IdType="pubmed">34222142</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire J.D., Vazquez S.N., Chan A., Smith M.E., Chellapandian D., Vose L., et al. Case report: secondary hemophagocytic lymphohistiocytosis with disseminated infection in chronic granulomatous disease&#x2014;a serious cause of mortality. Front Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756012</ArticleId><ArticleId IdType="pubmed">33362767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;ppi M.G., Jaquet V., Belli D.C., Krause K.H. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol. 2008;30:255&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509648</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagrecha A., Zhang M., Acharya S., Lozinsky S., Singer A., Levine C., et al. Hemophagocytic lymphohistiocytosis gene variants in multisystem inflammatory syndrome in children. Biology. 2022;11:417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8945334</ArticleId><ArticleId IdType="pubmed">35336791</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuhammour W., Yavuz L., Jain R., Abu Hammour K., Al-Hammouri G.F., El Naofal M., et al. Genetic and clinical characteristics of patients in the middle east with multisystem inflammatory syndrome in children. JAMA Netw Open. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9157271</ArticleId><ArticleId IdType="pubmed">35639375</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Rebou&#xe7;as C.B., Piergiorge R.M., dos Santos Ferreira C., Seixas Zeitel R. d.e., Gerber A.L., Rodrigues M.C.F., et al. Host genetic susceptibility underlying SARS-CoV-2-associated multisystem inflammatory syndrome in Brazilian children. Mol Med. 2022;28:153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9742658</ArticleId><ArticleId IdType="pubmed">36510129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J.L., Abel L. Mechanisms of viral inflammation and disease in humans. Science. 2021;374:1080&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8697421</ArticleId><ArticleId IdType="pubmed">34822298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordallo B., Bellas M., Cortez A.F., Vieira M., Pinheiro M. Severe COVID-19: what have we learned with the immunopathogenesis? Adv Rheumatol. 2020;60:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7506814</ArticleId><ArticleId IdType="pubmed">32962761</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano-Jaramillo L.M., Yamazaki-Nakashimada M.A., O&#x2019;Farrill-Romanillos P.M., Muzquiz Zerme&#xf1;o D., Scheffler Mendoza S.C., Venegas Montoya E., et al. COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico. J Clin Immunol. 2021;41:1463&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8191444</ArticleId><ArticleId IdType="pubmed">34114122</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudouris E.S., Pinto-Mariz F., Mendon&#xe7;a L.O., Aranda C.S., Guimar&#xe3;es R.R., Kokron C., et al. Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: a cross-sectional study. J Clin Immunol. 2021;81:1479&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221557</ArticleId><ArticleId IdType="pubmed">34164762</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus N., Frizinsky S., Hagin D., Ovadia A., Hanna S., Farkash M., et al. Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. Front Immunol. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7840610</ArticleId><ArticleId IdType="pubmed">33519822</ArticleId></ArticleIdList></Reference><Reference><Citation>Keitel V., Bode J.G., Feldt T., Walker A., M&#xfc;ller L., Kunstein A., et al. Case report: convalescent plasma achieves SARS-CoV-2 viral clearance in a patient with persistently high viral replication over 8 weeks due to severe combined immunodeficiency (SCID) and graft failure. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126709</ArticleId><ArticleId IdType="pubmed">34012436</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oers N.S.C., Hanners N.W., Sue P.K., Aquino V., Li Q.Z., Schoggins J.W., et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. Clin Immunol. 2021;224</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834850</ArticleId><ArticleId IdType="pubmed">33412294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamperlini-Netto G., Fernandes J.F., Garcia J.L., Ribeiro A.A.F., Camargo L.F.A., de Moraes Terra C., et al. COVID-19 after hematopoietic stem cell transplantation: report of two children. Bone Marrow Transplant. 2021;56:713&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">32934304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>